TFM
SRPT icon

TFC Financial Management’s Sarepta Therapeutics SRPT Stock Holding History

TFC Financial Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7
Closed -$120 – 1053
2025
Q2 		$120 Buy
+7
New +$299 ﹤0.01% 853
2025
Q1 		– Sell
-1
Closed -$122 – 1041
2024
Q4 		$122 Hold
1
– – ﹤0.01% 801
2024
Q3 		$125 Hold
1
– – ﹤0.01% 812
2024
Q2 		$158 Buy
+1
New +$128 ﹤0.01% 748
2023
Q4 		– Sell
-67
Closed -$8.12K – 725
2023
Q3 		$8.12K Buy
+67
New +$7.57K ﹤0.01% 360
2023
Q2 		– Sell
-2
Closed -$276 – 743
2023
Q1 		$276 Buy
+2
New +$259 ﹤0.01% 602
2022
Q1 		– Sell
-57
Closed -$5K – 580
2021
Q4 		$5K Buy
+57
New +$4.87K ﹤0.01% 397
2020
Q4 		– Sell
-15
Closed -$2K – 594
2020
Q3 		$2K Buy
+15
New +$2.28K ﹤0.01% 418

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

TFC Financial Management's SRPT Position: Q3 2025 in Review

TFC Financial Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 7 shares — an estimated $120 sold.

TFC Financial Management first reported a position in SRPT in Q3 2020 and held it in 8 quarters. The position peaked at $8.12K in Q3 2023. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • TFC Financial Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • TFC Financial Management sold 7 Sarepta Therapeutics shares in Q3 2025, an estimated $120.
  • TFC Financial Management first reported a position in Sarepta Therapeutics in Q3 2020 and held it in 8 quarters.
  • TFC Financial Management's Sarepta Therapeutics position peaked at $8.12K in Q3 2023.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on TFC Financial Management's 13F filing for Q3 2025, filed 24 Oct 2025.